


Item Number: 17	
Name of Presenter: Dr Shaun O'Connell	
Meeting of the Governing Body 4 June 2015	 Vale of York Clinical Commissioning Group
Meeting of Medicines Commissioning Committee	
Purpose of Report For Information	
1. Rationale These are the latest outcomes from the Medicines Commissioning Meeting	
2. Strategic Initiative <input checked="" type="checkbox"/> Integration of care <input type="checkbox"/> Person centred care <input type="checkbox"/> Primary care reform <input type="checkbox"/> Urgent care reform <input checked="" type="checkbox"/> Planned care <input type="checkbox"/> Transforming MH and LD services <input checked="" type="checkbox"/> Children and maternity <input checked="" type="checkbox"/> Cancer, palliative care and end of life care <input type="checkbox"/> System resilience	
3. Actions / Recommendations For information only	
4. Engagement with groups or committees Senior Management Team has accepted these recommendations	
5. Significant issues for consideration Rivaroxaban NICE TA 335 from April 2015 Medicines Commissioning Committee recommendations is on the Governing Body agenda at item 14	
6. Implementation Primary and secondary care are routinely informed.	
7. Monitoring None	
8. Responsible Chief Officer and Title Dr Shaun O'Connell GP Lead for Prescribing and Planned Care	9. Report Author and Title Laura Angus Lead Pharmacist
10. Annexes The March 2015 and April 2015 recommendations	